ProfileGDS5678 / 1451372_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 28% 77% 80% 27% 27% 29% 27% 27% 52% 26% 27% 28% 31% 27% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6813728
GSM967853U87-EV human glioblastoma xenograft - Control 25.3255577
GSM967854U87-EV human glioblastoma xenograft - Control 35.679180
GSM967855U87-EV human glioblastoma xenograft - Control 42.5711727
GSM967856U87-EV human glioblastoma xenograft - Control 52.5732627
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7353329
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6610327
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6068427
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.26352
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5962926
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6152627
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6076828
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7152931
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6185127